Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) 98.6% HIGHER; At ASCO yesterday, Keryx announced data on the clinical activity of KRX-0401 (perifosine), the Company’s Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Click here for the full report.

ARCA biopharma (Nasdaq: ABIO) 43.5% LOWER; received a Complete Response letter from the U.S.FDA for its New Drug Application seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Click here for the full report.

Antigenics Inc. (NASDAQ: AGEN) 35.6% HIGHER; today announced results of an interim analysis from the